Drug intelligence / Profile preview

recombinant human prourokinase

Development stage: Phase 4
Lead developer: Tasly Pharmaceutical
Modality: Metabolic Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
Administration: Intravenous

Overview

Recombinant human prourokinase (rhPro-UK) is a thrombolytic agent with an amino acid sequence identical to natural prourokinase. It functions as a plasminogen activator, converting plasminogen to plasmin which breaks down fibrin clots. It has been approved in China for treating acute myocardial infarction since 2011 and has also been studied in clinical trials for acute ischemic stroke and is in preregistration for pulmonary embolism.

Brand names: PuxinnuoMarosol
Other names: Recombinant human pro-urokinaseRecombinant human urokinase

Targets

PLG (Plasminogen)

Beyond the preview

Go deeper on recombinant human prourokinase.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on recombinant human prourokinase.